Personal information

No personal information available

Activities

Collapse all

Works (45)

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia

Blood Advances
2025-02-11 | Journal article
DOI: 10.1182/bloodadvances.2024014405
Contributors: Marlise R. Luskin; Shai Shimony; Julia Keating; Eric S. Winer; Jacqueline S. Garcia; Richard M. Stone; Elias Jabbour; Yael Flamand; Kristen Stevenson; Jeremy Ryan et al.
Source: check_circle
Crossref

Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia

Blood
2025-02-06 | Journal article
DOI: 10.1182/blood.2024025800
Contributors: Marlise R. Luskin; Mark A. Murakami; Julia Keating; Yael Flamand; Eric S. Winer; Jacqueline S. Garcia; Maximilian Stahl; Richard M. Stone; Martha Wadleigh; Stella L. Jaeckle et al.
Source: check_circle
Crossref

Sharpening the Tools to Get the Edge on Leukemia

American Journal of Hematology
2025-02-04 | Journal article
DOI: 10.1002/ajh.27622
Contributors: Shai Shimony; Jacqueline S. Garcia
Source: check_circle
Crossref

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes

Blood Journal
2024-12-09 | Journal article
DOI: 10.1182/blood.2024025464
Contributors: Jacqueline S. Garcia; Uwe Platzbecker; Olatoyosi Odenike; Shaun A Fleming; Chun Yew Fong; Uma Borate; Meagan A Jacoby; Daniel Nowak; Maria R Baer; Pierre Peterlin et al.
Source: check_circle
Crossref

A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies

Clinical Cancer Research
2024-11-01 | Journal article
DOI: 10.1158/1078-0432.CCR-24-0028
Contributors: Pinkal Desai; Sagar Lonial; Amanda Cashen; Manali Kamdar; Ian Flinn; Susan O’Brien; Jacqueline S. Garcia; Neha Korde; Javid Moslehi; Margaret Wey et al.
Source: check_circle
Crossref

Data from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies

2024-11-01 | Preprint
DOI: 10.1158/1078-0432.c.7520353
Contributors: Pinkal Desai; Sagar Lonial; Amanda Cashen; Manali Kamdar; Ian Flinn; Susan O’Brien; Jacqueline S. Garcia; Neha Korde; Javid Moslehi; Margaret Wey et al.
Source: check_circle
Crossref

Supplementary Table S1 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies

2024-11-01 | Preprint
DOI: 10.1158/1078-0432.27434296
Contributors: Pinkal Desai; Sagar Lonial; Amanda Cashen; Manali Kamdar; Ian Flinn; Susan O’Brien; Jacqueline S. Garcia; Neha Korde; Javid Moslehi; Margaret Wey et al.
Source: check_circle
Crossref

Supplementary Table S2 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies

2024-11-01 | Preprint
DOI: 10.1158/1078-0432.27434290
Contributors: Pinkal Desai; Sagar Lonial; Amanda Cashen; Manali Kamdar; Ian Flinn; Susan O’Brien; Jacqueline S. Garcia; Neha Korde; Javid Moslehi; Margaret Wey et al.
Source: check_circle
Crossref

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood
2024-10-24 | Journal article
DOI: 10.1182/blood.2024025802
Contributors: Ayalew Tefferi; Giovanni Barosi; Francesco Passamonti; Juan-Carlos Hernandez-Boluda; Prithviraj Bose; Konstanze Döhner; Martin Ellis; Naseema Gangat; Jacqueline S. Garcia; Heinz Gisslinger et al.
Source: check_circle
Crossref

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

2024-10-17 | Preprint
DOI: 10.52843/cassyni.7rmklq
Contributors: Jacqueline S. Garcia
Source: check_circle
Crossref

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias

Blood
2024-09-19 | Journal article
DOI: 10.1182/blood.2023022908
Contributors: Rahul S. Vedula; Hannah Q. Karp; Jeremy Koob; Felicia Lim; Jacqueline S. Garcia; Eric S. Winer; Marlise R. Luskin; Gabriel Ghiaur; Annette S. Kim; Lan W. Beppu et al.
Source: check_circle
Crossref

Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients

Leukemia
2024-07 | Journal article
DOI: 10.1038/s41375-024-02230-w
Contributors: Shai Shimony; Jacqueline S. Garcia; Julia Keating; Evan C. Chen; Marlise R. Luskin; Maximilian Stahl; Donna S. Neuberg; Daniel J. DeAngelo; Richard M. Stone; R. Coleman Lindsley
Source: check_circle
Crossref

Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial

Clinical Lymphoma Myeloma and Leukemia
2024-06 | Journal article
DOI: 10.1016/j.clml.2024.01.007
Contributors: Marina Y. Konopleva; Monique Dail; Naval G. Daver; Jacqueline S. Garcia; Brian A. Jonas; Karen W.L. Yee; Kevin R. Kelly; Norbert Vey; Sarit Assouline; Gail J. Roboz et al.
Source: check_circle
Crossref

Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia

American Journal of Hematology
2024-04 | Journal article
DOI: 10.1002/ajh.27246
Contributors: Keith W. Pratz; Brian A. Jonas; Vinod Pullarkat; Michael J. Thirman; Jacqueline S. Garcia; Hartmut Döhner; Christian Récher; Walter Fiedler; Kazuhito Yamamoto; Jianxiang Wang et al.
Source: check_circle
Crossref

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

Blood Advances
2024-02-27 | Journal article
DOI: 10.1182/bloodadvances.2023012120
Contributors: Jacqueline S. Garcia; Haesook T. Kim; H. Moses Murdock; Michela Ansuinelli; Jennifer Brock; Corey S. Cutler; Mahasweta Gooptu; Vincent T. Ho; John Koreth; Sarah Nikiforow et al.
Source: check_circle
Crossref

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

Blood Advances
2024-02-13 | Journal article
DOI: 10.1182/bloodadvances.2023011721
Contributors: Andrew A. Lane; Jacqueline S. Garcia; Evangeline G. Raulston; Jada L. Garzon; Ilene Galinsky; Emilie W. Baxter; Rebecca Leonard; Daniel J. DeAngelo; Marlise R. Luskin; Christopher R. Reilly et al.
Source: check_circle
Crossref

FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years

Blood Advances
2023-09-26 | Journal article
DOI: 10.1182/bloodadvances.2023009748
Contributors: Shai Shimony; Geoffrey Fell; Evan C. Chen; Harrison K. Tsai; Martha Wadleigh; Eric S. Winer; Jacqueline S. Garcia; Marlise R. Luskin; Maximilian Stahl; Donna S. Neuberg et al.
Source: check_circle
Crossref

Considerations for Drug Development in Myelodysplastic Syndromes

Clinical Cancer Research
2023-07-14 | Journal article
DOI: 10.1158/1078-0432.CCR-22-3348
Contributors: Mikkael A. Sekeres; Nina Kim; Amy E. DeZern; Kelly J. Norsworthy; Jacqueline S. Garcia; R. Angelo de Claro; Marc R. Theoret; Emily Y. Jen; Lori A. Ehrlich; Amer M. Zeidan et al.
Source: check_circle
Crossref

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia

Blood Advances
2023-06-27 | Journal article
DOI: 10.1182/bloodadvances.2022007728
Contributors: Elyse A. Olesinski; Karanpreet S. Bhatia; Aarthi N. Mahesh; Shazwina Rosli; Jameelah S. Mohamed; Wei Y. Jen; Nitin Jain; Jacqueline S. Garcia; Gee C. Wong; Melissa Ooi et al.
Source: check_circle
Crossref

Biology and therapeutic targeting of molecular mechanisms in MPNs

Blood
2023-04-20 | Journal article
DOI: 10.1182/blood.2022017416
Contributors: Joan How; Jacqueline S. Garcia; Ann Mullally
Source: check_circle
Crossref

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Blood
2023-04-13 | Journal article
DOI: 10.1182/blood.2022017686
Contributors: Jacqueline S. Garcia; Yael Flamand; Livius Penter; Michael Keng; Benjamin K. Tomlinson; Lourdes M. Mendez; Paul Koller; Nicole Cullen; Yohei Arihara; Kathleen Pfaff et al.
Source: check_circle
Crossref

Data from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532317
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Data from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6532317.v1
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Data from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486461
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Data from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486461.v1
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486458
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486455
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486458.v1
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486452.v1
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486449
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486455.v1
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486452
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486446
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486443
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486449.v1
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486446.v1
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Supplementary Table from Impact of <i>F</i><i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22486443.v1
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Blood
2023-03-16 | Journal article
DOI: 10.1182/blood.2022016362
Contributors: Naval G. Daver; Monique Dail; Jacqueline S. Garcia; Brian A. Jonas; Karen W. L. Yee; Kevin R. Kelly; Norbert Vey; Sarit Assouline; Gail J. Roboz; Stefania Paolini et al.
Source: check_circle
Crossref

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

American Journal of Hematology
2023-02 | Journal article
DOI: 10.1002/ajh.26771
Contributors: Amer M. Zeidan; Uma Borate; Daniel A. Pollyea; Andrew M. Brunner; Fernando Roncolato; Jacqueline S. Garcia; Robin Filshie; Olatoyosi Odenike; Anne Marie Watson; Ravitharan Krishnadasan et al.
Source: check_circle
Crossref

Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

Clinical Cancer Research
2022-07-01 | Journal article
DOI: 10.1158/1078-0432.CCR-21-3405
Contributors: Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan et al.
Source: check_circle
Crossref

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy

Journal of Clinical Oncology
2022-05-20 | Journal article
DOI: 10.1200/JCO.21.02188
Contributors: Claire N. Harrison; Jacqueline S. Garcia; Tim C.P. Somervaille; James M. Foran; Srdan Verstovsek; Catriona Jamieson; Ruben Mesa; Ellen K. Ritchie; Srinivas K. Tantravahi; Pankit Vachhani et al.
Source: check_circle
Crossref

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

Journal of Clinical Oncology
2022-03-10 | Journal article
DOI: 10.1200/JCO.21.01546
Contributors: Keith W. Pratz; Brian A. Jonas; Vinod Pullarkat; Christian Recher; Andre C. Schuh; Michael J. Thirman; Jacqueline S. Garcia; Courtney D. DiNardo; Vladimir Vorobyev; Nicola S. Fracchiolla et al.
Source: check_circle
Crossref

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

Blood Advances
2021-12-28 | Journal article
DOI: 10.1182/bloodadvances.2021005566
Contributors: Jacqueline S. Garcia; Haesook T. Kim; H. Moses Murdock; Corey S. Cutler; Jennifer Brock; Mahasweta Gooptu; Vincent T. Ho; John Koreth; Sarah Nikiforow; Rizwan Romee et al.
Source: check_circle
Crossref

Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials

Blood Advances
2021-11-09 | Journal article
DOI: 10.1182/bloodadvances.2021005148
Contributors: Andrew Hantel; Marlise R. Luskin; Jacqueline S. Garcia; Wendy Stock; Daniel J. DeAngelo; Gregory A. Abel
Source: check_circle
Crossref

Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re‐induction chemotherapy

American Journal of Hematology
2020-03 | Journal article
DOI: 10.1002/ajh.25692
Contributors: Jacqueline S. Garcia; Shruti Bhatt; Geoffrey Fell; Adam S. Sperling; Michael Burgess; Hasmik Keshishian; Binyam Yilma; Andrew Brunner; Donna Neuberg; Steven A. Carr et al.
Source: check_circle
Crossref

Peer review (2 reviews for 2 publications/grants)

Review activity for Blood cancer journal. (1)
Review activity for Leukemia (1)
How many people are using ORCID?